Danazol treatment of idiopathic myelofibrosis with severe anemia. - Concepedia

Concepedia

Publication | Closed Access

Danazol treatment of idiopathic myelofibrosis with severe anemia.

72

Citations

21

References

2000

Year

Francisco Cervantes, Juan Carlos Hernández‐Boluda, E. Nadal, E Montserrat

Abstract

Danazol, given at an appropriate dosage for a sufficient time, is an effective treatment for a substantial proportion of IM patients with severe anemia without marked splenomegaly or who have been previously splenectomized.

References

	Year	Citations
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments] Brigitte Dupriez, Pierre Morel, JL Demory, Blood	1996	520
Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis RJ Jacobson, A Salo, PJ Fialkow Blood	1978	490
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments] Brigitte Dupriez, Pierre Morel, JL Demory, Blood	1996	407
Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Philippe Guardiola, Jeanne E. Anderson, Giuseppe Bandini, PubMed	1999	277
Danazol for the Treatment of Idiopathic Thrombocytopenic Purpura Yeon S. Ahn, William J. Harrington, Sheryl R. Simon, New England Journal of Medicine ThrombopoiesisThrombosisIdiopathic Thrombocytopenic PurpuraAutoimmune DiseaseBlood Platelet	1983	276
Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients Giuseppe Visani, Carlo Finelli, U. Castelli, British Journal of Haematology	1990	193
Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups Francisco Cervantes, Giovanni Barosi, Jean‐Loup Demory, British Journal of Haematology Young Mmm PatientsPathologyMyeloid NeoplasiaHematological MalignancyTranslational Medicine	1998	186
Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis Francisco Cervantes, Arturo Pereira, Jordi Esteve, British Journal of Haematology ImmunohematologyDiagnosisPathologyLogistic AnalysisMyeloid Neoplasia	1997	179
A prognostic classification of myelofibrosis with myeloid metaplasia Giovanni Barosi, Carlo Berzuini, Lucio N. Liberato, British Journal of Haematology	1988	116
Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival Emmanuel C. Besa, Peter C. Nowell̀, Nancy L. Geller, Cancer Agnogenic Myeloid MetaplasiaPathologyGynecologyOvarian CancerMyeloid Neoplasia	1982	108

Page 1